MetALD: Overlapping Metabolic and Alcohol Risks May Accelerate Liver Disease: Hepatology Communications | doi:10.1097/HC9.0000000000001053.

What Did the Review Find?

Metabolic and alcohol-associated liver disease (MetALD) describes steatotic liver disease with at least one cardiometabolic risk factor and alcohol intake in the intermediate range: 140–350 g/week for women and 210–420 g/week for men. The review reports that roughly 10–20% of people with hepatic steatosis may meet MetALD criteria, although estimates vary substantially between studies.

Evidence reviewed links combined metabolic and alcohol exposure with faster fibrosis progression and higher risks of cirrhosis, decompensation, hepatocellular carcinoma and death. Alcohol intake is often underreported: in cited studies, adding the biomarker phosphatidylethanol (PEth) to self-report substantially increased MetALD classification.

Why Does It Matter?

Assessing metabolic risk and alcohol use separately may miss patients with both exposures. The authors support integrating alcohol assessment into MASLD care, metabolic screening into alcohol-associated liver disease care, and fibrosis risk assessment into evaluation of patients with dual exposures.

GastroAGI takeaway

Recognise MetALD as a dual-exposure risk state and assess both cardiometabolic health and alcohol use. The review argues for integrated care and better case-finding; it does not establish a new HCC surveillance threshold or a MetALD-specific drug treatment.